Chimerix engaged with 7 other biopharmas before choosing Jazz’s $935M deal—here’s why it won

Before Jazz Pharmaceuticals inked a $935 million deal for Chimerix earlier this month, the biotech had been in talks with six other pharmas and one biotech about several different potential offers.